Day One Appoints Garry Nicholson as Chairman of the Board of Directors
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated...
COVID-19
Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab
HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio...
CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249
- Presentation at ESMO 2022 by Collaborator, Bristol Myers Squibb -- BMS-986249 Phase 2 study ongoing - SOUTH SAN FRANCISCO,...
Microbot Medical Commenced its First Step in the Anticipated Regulatory Process for its LIBERTY® Robotic System
GLP Pre-Clinical Trial Commenced at a Leading Research Institute by Global Leaders in the Endovascular SpaceHINGHAM, Mass., Sept. 12, 2022...
Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK)
DALLAS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new...
MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress
YAVNE, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic...
Mersana Therapeutics Announces FDA Fast Track Designation Granted to XMT-1660 for the Treatment of Triple-Negative Breast Cancer
XMT-1660 currently being studied in a Phase 1 trial enrolling patients with breast, endometrial and ovarian cancersCAMBRIDGE, Mass., Sept. 12,...
Akari Therapeutics Announces $12.75 Million Registered Direct Offering
NEW YORK and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
- Hepion Collaborates with HepQuant and Summit Clinical Research to Evaluate Rencofilstat’s Impact on Hepatic Function and Numerous NASH Functional...
Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA
NDA Submission for Nyxol Eye Drops in First Indication on Track for Late 2022FARMINGTON HILLS, Mich., Sept. 12, 2022 (GLOBE...
SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022
– Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints –...
Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress
PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery...
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors
- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady...
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of...
Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials
Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa...
Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”),...
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
Revenue of US$51.7 million in the second quarter of 2022Loss from operations of US$(17.9) million and adjusted EBITDA1 of US$6.5...
New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress
Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared...
Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress
Dr. Todd E. Rasmussen provides HAV™ clinical update and surgical skills workshop at ICMMDURHAM, N.C., Sept. 09, 2022 (GLOBE NEWSWIRE)...
InflaRx to Present at Upcoming Scientific and Investor Conferences
JENA, Germany, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by...